Replies to post #165793 on Biotech Values

[DewDiligence]

Never heard of EPIRUS until today.

They were founded in 2011 and they keep a pretty low profile. Their business model is clearly directed toward FoB’s in emerging markets, so I don’t see them as major competition for the MNTA/BAX partnership.

According to the company’s fact sheet (http://www.epirusbiopharma.com/files/130711%20-%20EPIRUS%20Fact%20Sheet%20(Final).pdf ), Epirus has FoB’s in preclinical development for Humira, Avastin, Herceptin, and Rituxan.

[DewDiligence]

Epirus and Ranbaxy ink commercialization deal for Remicade FoB:

http://www.financialpost.com/markets/news/EPIRUS+Ranbaxy+Announce+Signing+BOW015+Licensing+Partnership+Broad+Range/9362660/story.html

EPIRUS Switzerland GmbH, a wholly-owned subsidiary of Boston-based EPIRUS Biopharmaceuticals, Inc., and Ranbaxy Laboratories Limited, a division of Daiichi Sankyo Company, today announced the signing of a licensing agreement for BOW015, a biosimilar infliximab, for the broad range of territories including India, selected South East Asian markets, North Africa and several other markets.

...EPIRUS and Ranbaxy will initially pursue the commercialization of BOW015...in India. EPIRUS recently announced successful Phase 3 data for BOW015 [#msg-91507828] and, in November, filed for market approval.

Subsequent to launch in India, Ranbaxy will pursue registration and commercialization of BOW015 in other territories in South East Asia, North Africa and selected other markets.

In exchange for the rights to BOW015 in the territories, EPIRUS will receive upfront, milestone, and royalty payments over the term of the agreement.

[DewDiligence]

EPRS inks FoB collaboration with China’s Livzon Mabpharm:

http://finance.yahoo.com/news/epirus-livzon-mabpharm-inc-enter-120000117.html

EPIRUS Biopharmaceuticals, Inc., a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced today that it has signed a royalty-bearing, multi-product collaboration agreement with Livzon Mabpharm Inc., a Chinese biotechnology company focused on the development, manufacture, and sale of antibody-based drugs.

…Under the terms of the agreement, EPIRUS and Livzon will work together to develop, manufacture, and commercialize up to five biosimilar products. The first collaboration product is EPIRUS’ Remicade biosimilar BOW015 (infliximab), which was recently approved in India [see below]. Livzon will conduct any additional development work necessary for the approval of BOW015 in China and Taiwan. Livzon will also serve as the preferred supplier of BOW015 in these territories, following a transfer of EPIRUS’ SCALE manufacturing platform. Livzon will be responsible for all commercialization activities in its territories.

Epirus went public via a reverse merger with ZLCS announced in Apr 2014 (#msg-100707725). EPRS has a collaboration with Ranbaxy (#msg-95745192) to develop a Remicade FoB for countries in South East Asia, North Africa, and India (where it is already approved).